Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Lisdexamfetamine Atc N06Ba12 Obg For The Period 01 08 24 31 07 25 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6367992

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab Atc R03Dx05 Obo For The Period 01 08 2024 31 07 2025 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6344888

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Colistin Atc J01Xb01 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6340118

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Medicines Containing The Active Substance Ustekinumab Atc L04Ac05

Deadline: 31 May 2026

Germany

Ref. No.: 6337480

EMD:Ref Document

Bid Value: Ref Document

58 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Albendazole Atc P02Ca03 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6337365

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Pomalidomide Atc L04Ax06 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6335525

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Open House Drug Rebate Agreements Dolutegravir And Rilpivirine Atc J05Ar21

Deadline: 05 Jun 2026

Germany

Ref. No.: 6330837

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Open House Drug Rebate Agreements Pazopanib Atc L01Ex03

Deadline: 05 Jun 2026

Germany

Ref. No.: 6330518

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Open House Drug Discount Agreements Pimecrolimus Atc D11Ah02

Deadline: 05 Jun 2026

Germany

Ref. No.: 6329785

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Lisdexamfetamine Atc N06Ba12 Obg For The Period 01 08 24 31 07 25 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6322269

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Medicines Containing The Active Ingredient Lanthanum Iii Carbonate Atc V03Ae03 In The Dosage Form Chewable Tablets

Deadline: 31 May 2026

Germany

Ref. No.: 6321582

EMD:Ref Document

Bid Value: Ref Document

58 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab Atc R03Dx05 Obo For The Period 01 08 2024 31 07 2025 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6320404

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Sustainable Solutions For Upgraded Smart Wearables And Equipment In Sport

Deadline: 31 Aug 2028

France

Ref. No.: 6318682

EMD:Ref Document

Bid Value: Ref Document

881 Days Left

Open House Drug Rebate Agreements Ribociclib Atc L01Ef02

Deadline: 05 Jun 2026

Germany

Ref. No.: 6317948

EMD:Ref Document

Bid Value: Ref Document

63 Days Left

Open House Biologics Discount Agreements 2024 05 Ustekinumab

Deadline: 31 Jul 2026

Germany

Ref. No.: 6313745

EMD:Ref Document

Bid Value: Ref Document

119 Days Left

Discover Tenders by E Book Reader Sector

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Discover Tenders by E Book Reader Sector

Filter Your Search

FREE Trial plan for all new users!